Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Seaside, Vanderbilt to co-develop M1 antagonists

Executive Summary

Vanderbilt University Medical Center has chosen CNS biotech Seaside Therapeutics to exclusively develop and optimize its small-molecule muscarinic acetylcholine subtype 1 (M1) antagonists for Fragile X syndrome, autism, and possibly other brain development disorders. Vanderbilt and Seaside will select lead candidates for further development.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register